bullish
BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term
610 Views31 Jul 2018 16:20
The US-listed BeiGene (BGNE US) aims to list in Hong Kong by raising USD1 billion via issuing new shares. The company plans to use the majority of...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside08 Aug 2018
- BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term31 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)23 Jul 2018
x